SCHEMBL2188003

SCHEMBL2188003

Cn1nc(C(=O)Nc2cccc(Cl)c2)c2cnc3ccccc3c21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ MAPT P10636 5/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ PPARG P37231 1/20 0.49
▸ NR2E3 Q9Y5X4 1/20 0.49
▸ NCOR2 Q9Y618 1/20 0.49
▸ RIPK1 Q13546 1/20 0.49
▸ MAOB P27338 1/20 0.48
▸ ELANE P08246 1/20 0.48
▸ GRM4 Q14833 2/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7914008 0.86 MEN1 (0.42) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL8144943 0.75 TP53 (0.42) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL30695131 0.73 RIPK1 (0.67) MEN1KMT2AMAPTALDH1A1HIF1A
SCHEMBL29176626 0.73 RIPK1 (0.67) MEN1KMT2AMAPTALDH1A1HIF1A
SCHEMBL8153723 0.71 TP53 (0.43) MEN1KMT2AMAPTSMN1; SMN2RIPK1
SCHEMBL9524250 0.70 HIF1A (0.58) MEN1KMT2AMAPTALDH1A1HIF1A
SCHEMBL9631835 0.69 MAPT (0.57) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL2186582 0.69 THRB (0.52) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL29176624 0.69 KDM4E (0.55) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL30695132 0.69 KDM4E (0.55) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 — — US claimed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 — — EP claimed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 — — WO claimed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 — — US disclosed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 — — US disclosed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 — — US disclosed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 — — EP disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 — — WO disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GRM5, GRM1, GRM3 MEN1 4701/4885KMT2A 1449/4885MAPT 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback